Disease name: Fibrodysplasia ossificans progressiva (FOP), also known as "stone man disease" or "Münchmeyer disease" Affected populations: FOP is an extremely rare disease that is estimated to ...

Their findings are published in the journal EMBO Molecular Medicine. Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder in which abnormal bone formation progressively replaces ...

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder that turns soft tissue to bone. A recently completed multi-year study will finally provide doctors the information ...

Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder.

Along with Frederick Kaplan, an orthopedic surgeon and molecular geneticist at the university, Shore was focused on finding the cause of fibrodysplasia ossificans progressiva (FOP), an extremely ...

The U.S. Food and Drug Administration (FDA) has granted andecaliximab a Rare Pediatric Disease Designation (RPDD) for the treatment of FOP. An RPDD designation is granted to potential treatments for ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

In a mouse model of fibrodysplasia ossificans progressiva (FOP)-a genetic condition causing abnormal bone growth in soft tissues-DDR2 deficiency markedly reduced heterotopic ossification.

It is also found in rare diseases such as Fibrodysplasia ossificans progressiva (FOP). By applying our cell-based gene therapy system to induce HO, we hope to analyze exactly how this abnormal process ...